Celcuity (NASDAQ:CELC) Trading 0.5% Higher

Celcuity Inc. (NASDAQ:CELCGet Free Report) shares shot up 0.5% during mid-day trading on Monday . The stock traded as high as $17.68 and last traded at $16.91. 716,917 shares traded hands during trading, an increase of 185% from the average session volume of 251,191 shares. The stock had previously closed at $16.83.

Analyst Ratings Changes

Several brokerages recently issued reports on CELC. HC Wainwright restated a “buy” rating and set a $27.00 price target on shares of Celcuity in a research note on Thursday, May 16th. Craig Hallum restated a “buy” rating and issued a $27.00 price objective (up previously from $25.00) on shares of Celcuity in a research report on Thursday, May 16th. Stifel Nicolaus reiterated a “buy” rating and set a $40.00 target price on shares of Celcuity in a research report on Thursday, May 16th. Finally, Needham & Company LLC lowered their price objective on shares of Celcuity from $24.00 to $23.00 and set a “buy” rating for the company in a research report on Friday, May 31st.

View Our Latest Stock Analysis on Celcuity

Celcuity Price Performance

The company has a debt-to-equity ratio of 0.28, a current ratio of 11.23 and a quick ratio of 11.23. The company’s 50-day simple moving average is $16.06 and its 200-day simple moving average is $16.30. The stock has a market capitalization of $591.44 million, a price-to-earnings ratio of -6.06 and a beta of 0.81.

Celcuity (NASDAQ:CELCGet Free Report) last announced its quarterly earnings data on Wednesday, May 15th. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.07. Research analysts forecast that Celcuity Inc. will post -2.85 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Celcuity

A number of institutional investors and hedge funds have recently made changes to their positions in CELC. SG Americas Securities LLC bought a new stake in Celcuity in the 4th quarter worth about $139,000. Trust Point Inc. bought a new position in Celcuity in the 4th quarter worth approximately $297,000. Pale Fire Capital SE lifted its stake in Celcuity by 38.4% in the 4th quarter. Pale Fire Capital SE now owns 14,409 shares of the company’s stock worth $210,000 after purchasing an additional 4,000 shares in the last quarter. Commodore Capital LP lifted its stake in Celcuity by 3.6% in the 4th quarter. Commodore Capital LP now owns 1,754,704 shares of the company’s stock worth $25,566,000 after purchasing an additional 60,563 shares in the last quarter. Finally, Perceptive Advisors LLC purchased a new stake in Celcuity in the 4th quarter worth approximately $21,583,000. Institutional investors and hedge funds own 63.33% of the company’s stock.

About Celcuity

(Get Free Report)

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.

Featured Articles

Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.